Tuberculosis

  • David C. Deitz

Abstract

For many primary-care physicians in Canada and the United States, tuberculosis has become a rare disease. The Centers for Disease Control (CDC) report 21,801 cases of tuberculosis in 1985, equivalent to a case rate of 9.1 per 100,000 population.1 This is still a significant public health problem, but when compared with estimates of over 500,000 physicians in the United States by 1990, it becomes clear that many North American physicians will not encounter the disease in regular practice. Advances in our understanding of how to detect, cure, and prevent tuberculosis have greatly changed the course of the disease. As the prevalence of active cases declines, the role of preventive strategies as implemented by individual physicians requires continued emphasis. The challenge for primary-care physicians for the future will be to identify groups and individuals at risk for tuberculosis, screen for infection when appropriate, and prescribe prophylaxis when indicated—all without necessarily encountering an active case for long intervals.2

Keywords

Hepatitis Neuropathy Candida Sarcoidosis Measle 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tuberculosis—United States, 1985—and the possible impact of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. Morbid. Mortal. Wkly. Rep. 35(5): 74–76, 1986.Google Scholar
  2. 2.
    Sbarbaro, J. A.: Tuberculosis: The new challenge to the practicing clinician. Chest 68(suppl. 3): 436–443, 1975.PubMedGoogle Scholar
  3. 3.
    Comstock, G. W., Livesay, V. T., and Woolpert, S. F.: The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 99: 131–138, 1974.PubMedGoogle Scholar
  4. 4.
    Ferebee, S. H., and Mount, F. W.: Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am. Rev. Respir. Dis. 85: 490–510, 1962.PubMedGoogle Scholar
  5. 5.
    Comstock, G. W.: Epidemiology of tuberculosis. Am. Rev. Respir. Dis. 125(3, part 2): 8–15, 1982.PubMedGoogle Scholar
  6. 6.
    Tuberculosis, in Annual Summary 1983. Morbid. Mortal. Wkly. Rep. 32(54): 62–65, 1984.Google Scholar
  7. 7.
    Tuberculosis—United States, 1984. Morbid. Mortal. Wkly. Rep. 34: 299–302, 307, 1985.Google Scholar
  8. 8.
    Chapman, J. S., and Dyerly, M. D.: Social and other factors in intrafamilial transmission of tuberculosis. Am. Rev. Respir. Dis. 90: 48–60, 1964.PubMedGoogle Scholar
  9. 9.
    Stead, W. W.: Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: Recrudescence of residuals of the primary infection or exogenous reinfection. Am. Rev. Respir. Dis. 95: 729–745, 1967.PubMedGoogle Scholar
  10. 10.
    Barry, M. A., Wall, C., Shirley, L., et al.: Tuberculosis screening in Boston’s homeless shelters. Public Health Rep. 101: 487–494, 1986.PubMedGoogle Scholar
  11. 11.
    Barrett-Connor, E.: The epidemiology of tuberculosis in physicians. JAMA 241: 33–38, 1979.PubMedGoogle Scholar
  12. 12.
    Chan, J. C., and Tabak, J. I.: Risk of tuberculous infection among house staff in an urban teaching hospital. South. Med. J. 78: 1061–1064, 1985.PubMedGoogle Scholar
  13. 13.
    Tuberculosis among Hispanics in the United States—1980. Morbid. Mortal. Wkly. Rep. 31: 237–239, 1982.Google Scholar
  14. 14.
    Pitchenik, A. E., Russell, B. W., Cleary, T., et al.: The prevalence of tuberculosis and drug-resistance among Haitians. N. Engl. J. Med. 307: 162–165, 1982.PubMedGoogle Scholar
  15. 15.
    Nolan, C. M., Aitken, M. L., Elarth, A. M., et al.: Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am. Rev. Respir. Dis. 133: 431–436, 1986.PubMedGoogle Scholar
  16. 16.
    Powell, K. E., Brown, E. D., and Farer, L. S.: Tuberculosis among Indochinese refugees in the United States. JAMA 249: 1455–1460, 1983.PubMedGoogle Scholar
  17. 17.
    Enarson, D., Ashley, M. J., and Grzybowski, S.: Tuberculosis in immigrants to Canada. Am. Rev. Respir. Dis. 119: 11–18, 1979.PubMedGoogle Scholar
  18. 18.
    Reichman, L. B., and O’Day, R.: Tuberculous infection in a large urban population. Am. Rev. Respir. Dis. 117: 705–712, 1978.PubMedGoogle Scholar
  19. 19.
    Bates, J. H.: Tuberculosis: Susceptibility and resistance. Am. Rev. Respir. Dis. 125(3, part 2): 20–24, 1982.PubMedGoogle Scholar
  20. 20.
    Stead, W. W.: The pathogenesis of pulmonary tuberculosis among older persons. Am. Rev. Respir. Dis. 91: 811–822, 1965.PubMedGoogle Scholar
  21. 21.
    Ferebee, S. H.: Controlled chemoprophylaxis trials in tuberculosis: A general review. Adv. Tuberc. Res. 17: 28–106, 1970.Google Scholar
  22. 22.
    Sutherland, I., Svandora, E., and Radhakrishna, S.: The development of clinical tuberculosis following infection with tubercle bacilli. Tubercle 63: 255–268, 1982.PubMedGoogle Scholar
  23. 23.
    Stead, W. W.: Does the risk of tuberculosis increase in old age. J. Infect. Dis. 147: 951–955, 1983.PubMedGoogle Scholar
  24. 24.
    Grzybowski, S., and Allen, E. A.: The challenge of tuberculosis in decline. Am. Rev. Respir. Dis. 90: 707–720, 1964.PubMedGoogle Scholar
  25. 25.
    Styblo, K.: Recent advances in epidemiological research in tuberculosis. Adv. Tuberc. Res. 20: 1–63, 1980.PubMedGoogle Scholar
  26. 26.
    Horwitz, O., Wilbek, E., and Erickson, P. A.: Epidemiological basis of tuberculosis eradication. Bull. WHO 41: 95–113, 1969.PubMedGoogle Scholar
  27. 27.
    Edwards, L. B., Acquaviva, F. A., and Livesay, V. T.: Identification of tuberculosis infected: Dual tests and density of reaction. Am. Rev. Respir. Dis. 108: 1334–1339, 1973.PubMedGoogle Scholar
  28. 28.
    Comstock, G. W., and Palmer, C. E.: Long-term results of BCG vaccination in the Southern U.S. Am. Rev. Respir. Dis. 93: 171–183, 1966.PubMedGoogle Scholar
  29. 29.
    Edwards, L. B., Livesay, V. T., Acquaviva, F. A., et al.: Height, weight, tuberculous infection and tuberculous disease. Arch. Environ. Health 22: 106–112, 1971.PubMedGoogle Scholar
  30. 30.
    Al-Arif, L. I., Goldstein, R. A., Affronti, L. F., et al.: HLA-BW15 and tuberculosis in a North American black population. Am. Rev. Respir. Dis. 120: 1275–1278, 1979.PubMedGoogle Scholar
  31. 31.
    Hwang, C. H., Khan, S., Ende, N., et al.: The HLA-A,-B and-DR phenotypes and tuberculosis. Am. Rev. Respir. Dis. 132: 382–385, 1985.PubMedGoogle Scholar
  32. 32.
    Bailey, W. C., Byrd, R. B., Glassroth, J. L., et al.: National Consensus Conference on Tuberculosis: Preventive treatment of tuberculosis. Chest 87(2, suppl. 10): 128S–132S, 1985.PubMedGoogle Scholar
  33. 33.
    Hudolin, V.: Tuberculosis and alcoholism. Ann. NY Acad. Sci. 252: 353–364, 1975.PubMedGoogle Scholar
  34. 34.
    Smith, F. E., and Palmer, D. L.: Alcoholism, infection and altered host defenses: A review of clinical and experimental observations. J. Chronic Dis. 29: 35–49, 1976.PubMedGoogle Scholar
  35. 35.
    Milne, R. C.: Alcoholism and tuberculosis in Victoria. Med. J. Austr. 2: 955–960, 1970.Google Scholar
  36. 36.
    Olin, J. S., and Grzybowski, J.: Tuberculosis and alcoholism. Can. Med. Assoc. J. 94: 999–1001, 1966.PubMedGoogle Scholar
  37. 37.
    Burach, W. R., and Hollister, R. M.: Tuberculous peritonitis. Am. J. Med. 28: 510–523, 1960.Google Scholar
  38. 38.
    Kok-Jensen, A.: Pulmonary tuberculosis in well-treated alcoholics. Long-term prognosis regarding relapses compared with non-alcoholic patients. Scand. J. Respir. Dis. 53: 202–206, 1972.PubMedGoogle Scholar
  39. 39.
    Hudson, L. D., and Sbarbaro, J. A.: Twice weekly tuberculosis chemotherapy. JAMA 223: 139–143, 1973.PubMedGoogle Scholar
  40. 40.
    Lewis, J. G., and Chamberlain, D. A.: Alcohol consumption and smoking habits in male patients with pulmonary tuberculosis. Br. J. Prev. Soc. Med. 17: 149–152, 1963.PubMedGoogle Scholar
  41. 41.
    Segarra, F., and Sherman, D. S.: Relapses in pulmonary tuberculosis. Dis. Chest. 51: 59–63, 1967.PubMedGoogle Scholar
  42. 42.
    Glassroth, J., Robins, A. G., and Snider, D. E., Jr.: Tuberculosis in the 1980’s. N. Engl. J. Med. 302: 1441–1450, 1980.PubMedGoogle Scholar
  43. 43.
    Luelmo, F.: BCG vaccination. Am. Rev. Respir. Dis. 125(3, part 2): 70–72, 1982.PubMedGoogle Scholar
  44. 44.
    ten Dam, H. G.: Research on BCG vaccination. Adv. Tuberc. Res. 21: 79–106, 1984.PubMedGoogle Scholar
  45. 45.
    Clemens, J. D., Chuong, J. J. H., and Feinstein, A. R.: The BCG controversy: A methodological and statistical reappraisal. JAMA 249: 2362–2369, 1983.PubMedGoogle Scholar
  46. 46.
    British Thoracic Association: Effectiveness of BCG vaccination in Great Britain in 1978. Br. J. Dis. Chest 74: 215–227, 1980.Google Scholar
  47. 47.
    Young, T. K.: BCG vaccination among Canadian Indians and Inuit: The epidemiological bases for policy decision. Can. J. Public Health 76: 124–129, 1985.PubMedGoogle Scholar
  48. 48.
    Lotte, A., Wasz-Hockert, O., Poisson, N., et al.: BCG complications. Adv. Tuberc. Res. 21: 107–193, 1984.PubMedGoogle Scholar
  49. 49.
    Adult immunization: Recommendations of the Immunization Practices Advisory Committee. Morbid. Mortal. Wkly. Rep. 33(15), 1984.Google Scholar
  50. 50.
    Rust, P., and Thomas, J.: A method for estimating the prevalence of tuberculous infection. Am. J. Epidemiol. 101: 311–322, 1975.PubMedGoogle Scholar
  51. 51.
    Edwards, L. B., Acquaviva, F. A., Livesay, V. T., et al.: An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am. Rev. Respir. Dis. 99(suppl.): 1–132, 1969.PubMedGoogle Scholar
  52. 52.
    Moulding, T.: Chemoprophylaxis of tuberculosis: When is the benefit worth the risk and cost. Ann. Intern. Med. 74: 761–770, 1971.PubMedGoogle Scholar
  53. 53.
    Feingold, A. O.: Cost-effectiveness of screening for tuberculosis in a general medical clinic. Public Health Rep. 90: 545–547, 1975.Google Scholar
  54. 54.
    Stead, W. W.: Tuberculosis among elderly persons: An outbreak in a nursing home. Ann. Intern. Med. 94: 606–610, 1981.PubMedGoogle Scholar
  55. 55.
    Stead, W. W., Lofgren, J. P., Warren, E., et al.: Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N. Engl. J. Med. 312: 1483–1487, 1985.PubMedGoogle Scholar
  56. 56.
    Tuberculosis in a nursing care facility—Washington. Morbid. Mortal. Wkly. Rep. 32: 121–122, 1983.Google Scholar
  57. 57.
    Tuberculosis in a nursing home—Oklahoma. Morbid. Mortal. Wkly. Rep. 29: 465–467, 1980.Google Scholar
  58. 58.
    Stead, W. W.: Undetected tuberculosis in prison. JAMA 240: 2544–2547, 1978.PubMedGoogle Scholar
  59. 59.
    American Thoracic Society: The tuberculin skin test. Am. Rev. Respir. Dis. 124: 356–363, 1981.Google Scholar
  60. 60.
    Sokal, J. E.: Measurement of delayed skin-test responses. N. Engl. J. Med. 293: 501–502, 1975.PubMedGoogle Scholar
  61. 61.
    Snider, D. E., Jr.: The tuberculin skin test. Am. Rev. Respir. Dis. 125(3, part 2): 108–118, 1982.PubMedGoogle Scholar
  62. 62.
    Bass, J. B., Sanders, R. V., and Kirkpatrick, M. B.: Choosing an appropriate cutting point for conversion in annual tuberculin skin testing. Am. Rev. Respir. Dis. 132: 379–381, 1985.PubMedGoogle Scholar
  63. 63.
    Snider, D. E., Jr.: Bacille Calmette-Guerin vaccinations and tuberculin skin tests. JAMA 253: 3438–3439, 1985.PubMedGoogle Scholar
  64. 64.
    Comstock, G. W., Edwards, L. B., and Nabangxang, H.: Tuberculin sensitivity eight to fifteen years after BCG vaccination. Am. Rev. Respir. Dis. 103: 572–575, 1971.PubMedGoogle Scholar
  65. 65.
    Kent, D. C., and Schwartz, R.: Active pulmonary tuberculosis with negative tuberculin skin reactions. Am. Rev. Respir. Dis. 95: 411, 1967.PubMedGoogle Scholar
  66. 66.
    Holden, M., Dubin, M. R., and Diamond, P. H.: Frequency of negative intermediate-strength tuberculin sensitivity in patients with active tuberculosis. N. Engl. J. Med. 285: 1506–1509, 1974.Google Scholar
  67. 67.
    Rooney, J. J., Crocco, J. A., Kramer, S., et al.: Further observations on tuberculin reactions in active tuberculosis. Am. J. Med. 60: 517–522, 1976.PubMedGoogle Scholar
  68. 68.
    Comstock, G. W.: False tuberculin test results. Chest 68(3, suppl.): 465–469, 1975.PubMedGoogle Scholar
  69. 69.
    Chaparas, S. D., Vandiviere, H. M., Melvin, I., et al.: Tuberculin test: Variability with the Mantoux procedure. Am. Rev. Respir. Dis. 132: 175–178, 1985.PubMedGoogle Scholar
  70. 70.
    Thompson, N. J., Glassroth, J. L., Snider, D. E., Jr., et al.: The booster phenomenon in serial tuberculin testing. Am. Rev. Respir. Dis. 119: 587–597, 1979.PubMedGoogle Scholar
  71. 71.
    Ferebee, S. H., and Mount, F. W.: Evidence of booster effect in serial tuberculin testing. Am. Rev. Respir. Dis. 88: 118–119, 1963.Google Scholar
  72. 72.
    Lunn, J. A.: Tuberculin tine tests: Effect of variations in dried tuberculin coating. Tubercle 62: 241–248, 1981.PubMedGoogle Scholar
  73. 73.
    Osborn, T. W.: Some factors influencing the tuberculin tine test. Tubercle 63: 45–54, 1982.PubMedGoogle Scholar
  74. 74.
    Lunn, J. A., Johnson, A. J., and Fry, J. S.: Comparison of multiple puncture liquid tuberculin test with Mantoux test. Lancet 1: 695–698, 1981.PubMedGoogle Scholar
  75. 75.
    Rudd, R. M., Gellert, A. R., and Venning, M.: Comparison of Mantoux, tine and “Imotest” tuberculin tests. Lancet 2: 515–518, 1982.PubMedGoogle Scholar
  76. 76.
    Lunn, J. A., and Johnson, A. J.: Comparison of the tine and Mantoux tuberculin tests. Br. Med. J. 1: 451–1453, 1978.Google Scholar
  77. 77.
    Sinclair, D. J. M., and Johnston, R. N.: Assessment of tine tuberculin test. Br. Med. J. 1: 1325–26, 1979.PubMedGoogle Scholar
  78. 78.
    Donaldson, J. C., and Elliott, R. C.: A study of co-positivity of three multipuncture techniques with intradermal PPD tuberculin. Am. Rev. Respir. Dis. 118: 843–846, 1978.PubMedGoogle Scholar
  79. 79.
    British Thoracic Association—Research Committee: Reproducibility of the tine tuberculin test. Br. J. Dis. Chest 76: 75–78, 1982.Google Scholar
  80. 80.
    Kearns, T. J., Cole, C. H., Farer, L. S., et al.: National Consensus Conference on Tuberculosis. Public health issues in control of tuberculosis: Surveillance techniques and the role of health care providers. Chest 87(2, suppl.): 135S–138S, 1985.PubMedGoogle Scholar
  81. 81.
    Sbarbaro, J. A.: The FDA’s final decision concerning the tuberculin multiple puncture test. Am. Rev. Respir. Dis. 120: 1390–1391, 1979.PubMedGoogle Scholar
  82. 82.
    Daniel, T. M., Debanne, S. M., van der Kuyp, F.: Enzyme-linked immunosorbent assay usin. Mycobac-terium tuberculosis antigen 5 and PPD for the serodiagnosis of tuberculosis. Chest 88: 388–392, 1985.PubMedGoogle Scholar
  83. 83.
    Zeiss, C. R., Kalish, S. B., Erlich, K. S., et al.: IgG antibody to purified protein derivative by enzyme-linked immunosorbent assay in the diagnosis of pulmonary tuberculosis. Am. Rev. Respir. Dis. 130: 845–848, 1984.PubMedGoogle Scholar
  84. 84.
    Bass, J. B., Jr., Farer, L. S., Hopewell, P. C., et al.: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis. 134: 355–363, 1986.Google Scholar
  85. 85.
    Comstock, G. W., Ferebee, S. H., and Hammes, L. H.: A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am. Rev. Respir. Dis. 95: 935–943, 1967.PubMedGoogle Scholar
  86. 86.
    International Union Against Tuberculosis Committee on Prophylaxis: Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. Bull. WHO 60: 555–564, 1982.Google Scholar
  87. 87.
    Ferebee, S. H., Mount, F. W., Murray, F. J., et al.: A controlled trial of isoniazid prophylaxis in mental institutions. Am. Rev. Respir. Dis. 88: 161–175, 1963.PubMedGoogle Scholar
  88. 88.
    Farer, L. S.: Chemoprophylaxis. Am. Rev. Respir. Dis. 125(3, part 2): 102–107, 1982.PubMedGoogle Scholar
  89. 89.
    Comstock, G. W., Baum, C., and Snider, D. E., Jr.: Isoniazid prophylaxis among Alaska Eskimos: A final report of the Bethel isoniazid studies. Am. Rev. Respir. Dis. 119: 827–830, 1979.PubMedGoogle Scholar
  90. 90.
    Dash, L. A., Comstock, G. W., and Flynn, J. P. G.: Isoniazid preventive therapy: Retrospect and prospect. Am. Rev. Respir. Dis. 121: 1039–1044, 1980.PubMedGoogle Scholar
  91. 91.
    Kopanoff, D. E., Snider, D. E., Jr., and Caras, G. J.: Isoniazid-related hepatitis: A U.S. Public Health Service cooperative surveillance study. Am. Rev. Respir. Dis. 117: 991–1001, 1978.PubMedGoogle Scholar
  92. 92.
    Comstock, G. W., and Edwards, P. Q.: The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. Am. Rev. Respir. Dis. 111: 573–577, 1975.PubMedGoogle Scholar
  93. 93.
    Taylor, W. C., Aronson, M. D., and Delbanco, T. L.: Should young adults with a positive tuberculin test take isoniazid. Ann. Intern. Med. 94: 808–813, 1981.PubMedGoogle Scholar
  94. 94.
    Rose, D. N., Schechter, C. B., and Silver, A.: The age threshold for isoniazid chemoprophylaxis: A decision analysis for low-risk tuberculin reactors. JAMA 256: 2709–2713, 1986.PubMedGoogle Scholar
  95. 95.
    Comstock, G. W.: Evaluating isoniazid preventive therapy: The need for more data. Ann. Intern. Med. 94: 817–819, 1981.PubMedGoogle Scholar
  96. 96.
    Comstock, G. W.: Prevention of tuberculosis among tuberculin reactors: Maximizing benefits, minimizing risks. JAMA 256: 2729–2730, 1986.PubMedGoogle Scholar
  97. 97.
    Byrd, R. B., Horn, B. R., Solomon, D. A., et al.: Toxic effects of isoniazid in tuberculosis chemoprophylaxis. JAMA 241: 1239–1241, 1979.PubMedGoogle Scholar
  98. 98.
    Falk, A., and Fuchs, G. F.: Prophylaxis with isoniazid in inactive tuberculosis. Chest 73: 44–48, 1978.PubMedGoogle Scholar
  99. 99.
    Snider, D. E., Jr., Caras, G. J., and Koplan, J. P.: Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy. JAMA 255: 1579–1583, 1986.PubMedGoogle Scholar
  100. 100.
    Sachs, J. J., Brenner, E. R., Breeden, D. C., et al.: Epidemiology of a tuberculosis outbreak in a South Carolina junior high school. Am. J. Public Health 75: 361–365, 1985.Google Scholar
  101. 101.
    Houk, V. N., Baker, J. H., Sorensen, K., et al.: The epidemiology of tuberculosis infection in a closed environment. Arch. Environ. Health 16: 26–35, 1968.PubMedGoogle Scholar
  102. 102.
    Stead, W. W., Kerby, G. R., Schlereter, D. P., et al.: The clinical spectrum of primary tuberculosis in adults. Ann. Intern. Med. 68: 731–745, 1968.PubMedGoogle Scholar
  103. 103.
    Khan, M. A., Kovnat, D. M., Bachus, B., et al.: Clinical and roentgenographic spectum of pulmonary tuberculosis in the adult. Am. J. Med. 62: 31–38, 1977.PubMedGoogle Scholar
  104. 104.
    Farer, L. S., Lowell, A. M., and Meador, M. P.: Extrapulmonary tuberculosis in the United States. Am. J. Epidemiol. 109: 205–217, 1979.PubMedGoogle Scholar
  105. 105.
    Alvarez, S., and McCabe, W. R.: Extrapulmonary tuberculosis revisited: A review of experience at Boston City and other hospitals. Medicine 63: 25–55, 1984.PubMedGoogle Scholar
  106. 106.
    Weir, M. R., and Thornton, G. F.: Extrapulmonary tuberculosis: Experience of a community hospital and review of the literature. Am. J. Med. 79: 467–478, 1985.PubMedGoogle Scholar
  107. 107.
    Page, M. I., and Lunn, J. S.: Experience with tuberculosis in a public teaching hospital. Am. J. Med. 77: 667–670, 1984.PubMedGoogle Scholar
  108. 108.
    Pitlik, S. D., Fainstein, V., and Bodey, G.: Tuberculosis mimicking cancer—A reminder. Am. J. Med. 76: 822–825, 1984.PubMedGoogle Scholar
  109. 109.
    MacGregor, R. R.: A year’s experience with tuberculosis in a private urban teaching hospital in the post sanatorium era. Am. J. Med. 58: 221–228, 1975.PubMedGoogle Scholar
  110. 110.
    Bobrowitz, I. D.: Active tuberculosis undiagnosed until autopsy. Am. J. Med. 72: 650–658, 1982.PubMedGoogle Scholar
  111. 111.
    D’Esopo, N. D.: Clinical trials in pulmonary tuberculosis. Am. Rev. Respir. Dis. 125(3, part 2): 85–93, 1982.PubMedGoogle Scholar
  112. 112.
    Stead, W. W., and Dutt, A. K.: Chemotherapy for tuberculosis today. Am. Rev. Respir. Dis. 125(3, part 2): 94–101, 1982.PubMedGoogle Scholar
  113. 113.
    Fox, W.: The chemotherapy of pulmonary tuberculosis: A review. Chest 76(suppl. 6): 785–796, 1979.PubMedGoogle Scholar
  114. 114.
    Snider, D. E., Jr., Long, M. W., Cross, F. S., et al.: Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Am. Rev. Respir. Dis. 129: 573–579, 1984.PubMedGoogle Scholar
  115. 115.
    National Consensus Conference on Tuberculosis: Standard therapy for tuberculosis 1985. Chest 87(suppl. 2): 117S–124S, 1985.Google Scholar
  116. 116.
    Addington, W. W.: Patient compliance: The most serious remaining problem in the control of tuberculosis in the United States. Chest 76: 741–743, 1976.Google Scholar
  117. 117.
    Sbarbaro, J. A.: Compliance: Inducements and enforcements. Chest 76: 750–755, 1979.PubMedGoogle Scholar
  118. 118.
    National Consensus Conference on Tuberculosis: Non-drug issues related to the treatment of tuberculosis. Chest 87(2, suppl.): 125S–127S, 1985.Google Scholar
  119. 119.
    Grzybowski, S.: Chemoprophylaxis in inactive tuberculosis: Long-term evaluation of a Canadian trial. Can. Med. Assoc. J. 114: 607–611, 1976.PubMedGoogle Scholar
  120. 120.
    LaForce, F. M., Huher, G. L., and Fahey, J. M.: The focality of urban tuberculosis. Am. Rev. Respir. Dis. 108: 553–558, 1973.PubMedGoogle Scholar
  121. 121.
    Drug-resistant tuberculosis among the homeless—Boston. Morbid. Mortal. Wkly. Rep. 34(28): 429–431, 1985.Google Scholar
  122. 122.
    McAdam, J., Brickner, P. W., Glicksman, R., et al.: Tuberculosis in the SRO/homeless population, in Brickner, P. W., Scharer, L. K., Conanan, B., et al. (eds.): Health Care of Homeless People. Springer, New York, pp. 155–175.Google Scholar
  123. 123.
    Nardell, E., McInnis, B., Thomas, B., et al.: Exogenous reinfection with tuberculosis in a shelter for the homeless. N. Engl. J. Med. 315: 1570–1575, 1986.PubMedGoogle Scholar
  124. 124.
    Koplan, J. P., and Farer, L. S.: Choice of preventive treatment for isoniazid-resistant tuberculous infection. JAMA 244: 2736–2740, 1980.PubMedGoogle Scholar
  125. 125.
    Tuberculosis: Cases of specified notifiable diseases, United States, weeks ending Dec. 27, 1986 and Dec. 28, 1985. Morbid. Mortal. Wkly. Rep. 35: 799–801, 1987.Google Scholar
  126. 126.
    Tuberculosis and acquired immunodeficiency syndrome—Florida. Morbid. Mortal. Wkly. Rep. 35(37): 587–590, 1986.Google Scholar
  127. 127.
    Pitchenik, A. E., Cole, C., Russell, B. W., et al.: Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in South Florida. Ann. Intern. Med. 101: 641–645, 1984.PubMedGoogle Scholar
  128. 128.
    Sunderam, G., McDonald, R. J., Maniatis, T., et al.: Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). JAMA 256: 362–366, 1986.PubMedGoogle Scholar
  129. 129.
    Curran, J. W., Morgan, W. M., Hardy, A. M., et al.: The epidemiology of AIDS: Current status and future prospects. Science 229: 1352–1357, 1985.PubMedGoogle Scholar
  130. 130.
    Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. Morbid. Mortal. Wkly. Rep. 35(28): 448–452, 1986.Google Scholar
  131. 131.
    Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. Morbid. Mortal. Wkly. Rep. 34(16): 227–228, 1985.Google Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • David C. Deitz
    • 1
  1. 1.Division of General Medicine and Primary Care, Department of MedicineBeth Israel Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations